Haemonetics Corporation (HAE)
57.17
0.28 (0.49%)
At close: Apr 17, 2025, 3:59 PM
0.49% (1D)
| Bid | 55.38 |
| Market Cap | 2.87B |
| Revenue (ttm) | 1.37B |
| Net Income (ttm) | 130.06M |
| EPS (ttm) | 2.54 |
| PE Ratio (ttm) | 22.51 |
| Forward PE | 11.52 |
| Analyst | Buy |
| Ask | 59.13 |
| Volume | 555,604 |
| Avg. Volume (20D) | 999,938 |
| Open | 57.16 |
| Previous Close | 56.89 |
| Day's Range | 56.74 - 58.38 |
| 52-Week Range | 55.30 - 97.97 |
| Beta | 0.41 |
About HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their d...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 10, 1991
Employees 3,657
Stock Exchange NYSE
Ticker Symbol HAE
Website https://www.haemonetics.com
Analyst Forecast
According to 9 analyst ratings, the average rating for HAE stock is "Buy." The 12-month stock price forecast is $104, which is an increase of 81.91% from the latest price.
Stock ForecastsNext Earnings Release
Haemonetics Corporation is scheduled to release its earnings on May 8, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-11.58%
Haemonetics shares are trading lower after the com...
Unlock content with
Pro Subscription
5 months ago
+10.71%
Haemonetics shares are trading higher after the company reported better-than-expected Q2 financial results.
